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Anxiety disorders have been linked to an increased risk of incident coronary heart disease
in which inflammation plays a key pathogenic role. To date, no studies have looked at the
association between proinflammatory markers and agoraphobia.
Methods
In a random Swiss population sample of 2890 persons (35-67 years, 53% women), we diag-
nosed a total of 124 individuals (4.3%) with agoraphobia using a validated semi-structured
psychiatric interview. We also assessed socioeconomic status, traditional cardiovascular
risk factors (i.e., body mass index, hypertension, blood glucose levels, total cholesterol/
high-density lipoprotein-cholesterol ratio), and health behaviors (i.e., smoking, alcohol con-
sumption, and physical activity), and other major psychiatric diseases (other anxiety disor-
ders, major depressive disorder, drug dependence) which were treated as covariates in
linear regression models. Circulating levels of inflammatory markers, statistically controlled
for the baseline demographic and health-related measures, were determined at a mean fol-
low-up of 5.5 ± 0.4 years (range 4.7 – 8.5).
Results
Individuals with agoraphobia had significantly higher follow-up levels of C-reactive protein
(p = 0.007) and tumor-necrosis-factor-α (p = 0.042) as well as lower levels of the
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cardioprotective marker adiponectin (p = 0.032) than their non-agoraphobic counterparts.
Follow-up levels of interleukin (IL)-1β and IL-6 did not significantly differ between the
two groups.
Conclusions
Our results suggest an increase in chronic low-grade inflammation in agoraphobia over
time. Such a mechanism might link agoraphobia with an increased risk of atherosclerosis
and coronary heart disease, and needs to be tested in longitudinal studies.
Introduction
Increasing evidence suggests that anxiety disorders are linked to elevated levels of circulating
biomarkers indicating low-grade inflammation. Based on experimental data, it has been hy-
pothesized that it is particularly the experience of acute stress in anxiety states, which leads to
these increments [1]. Most of the research on the association between anxiety disorders and in-
flammation stems from studies on posttraumatic stress disorder (PTSD) and the referring po-
tential pathophysiological pathways have extensively been described [2–5]. It is assumed, that a
prolonged or excessive activation of the acute stress response system in PTSD may increase the
risk for excessive systemic inflammation [6, 7] by long-term adaptations of bodily systems.
One such adaptation might consist of a decrease of cortisol levels and a consecutively insuffi-
cient glucocorticoid signaling, causing excessive levels of cell-mediated and proinflammatory
cytokines, as well as excessive stimulation of the hypothalamic-pituitary-adrenal (HPA) axis
[8–10].
However, it may also well be that the presence of a proinflammatory state precedes the actu-
al development of PTSD [7, 11]. Since not all trauma-exposed individuals subsequently develop
PTSD [12], it is hypothesized that the development of PTSD is associated with biological vul-
nerability factors, which are already present before the onset of symptoms. In a recent review,
such pre-existing vulnerability factors in the glucocorticoid signaling pathway for the develop-
ment of PTSD have been presented [5].
Sparse evidence from relatively small clinical studies also suggests that inflammatory activity
is increased in patients with panic disorder [13] and generalized anxiety disorder [14].
In comparison to PTSD, knowledge about the association between inflammation and agora-
phobia is scarce—despite the fact that agoraphobia is one of the most prevalent, persistent and
disabling of the mental disorders [15], with a well-known poor prognosis and frequent incom-
plete remission [15, 16]. Therefore it is a lifetime diagnosis in most of the cases. The main clini-
cal feature of agoraphobia is the presence of anxiety about being in places or situations from
which escape may be difficult (or embarrassing) or in which help may not be available in the
case of a panic attack or the occurrence of panic-like symptoms [17, 18].
Two studies that have investigated inflammation in patients with agoraphobia and panic at-
tacks so far did not show increased levels of inflammatory markers. However, measurements in
one small study on 36 patients with agoraphobia and panic attacks were performed after in
vitro stimulation of immune competent cells and, moreover, might be confounded by a four-
arm pharmacological intervention design [19]. The other recent population-based study found
no significant associations of circulating levels of C-reactive protein (CRP), tumor necrosis fac-
tor (TNF)-α, and interleukin (IL)-6 in individuals with a current panic disorder and/or
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agoraphobia [20]. However, that study did not investigate an association between inflamma-
tion and agoraphobia separately and applied a cross-sectional design [20].
To date, there is no study that has investigated whether patients with agoraphobia show in-
creased low-grade inflammation compared to individuals without agoraphobia, and whether
agoraphobic individuals show an increase of low-grade inflammation over time in comparison
to their non-agoraphobic counterparts, reflecting a cumulative and progressive immune
function dysregulation.
The following study aimed to address this existing research gap by examining the associa-
tion between agoraphobia and low-grade inflammation in a large population based sample.
Thereby, changes in circulating levels of inflammatory markers, that is CRP, IL-1β, IL-6, TNF-
α, and adiponectin, in patients with agoraphobia compared to those without this anxiety disor-
der were assessed prospectively, taking potential confounding factors commonly associated
with inflammation activity, and other relevant psychiatric disorders (including other anxiety
disorders), into account. We hypothesized that individuals with a lifetime diagnosis of agora-
phobia might have higher levels of proinflammatory markers and lower levels of the “cardio-
protective” adipo(cyto)kine adiponectin [21] than non-agoraphobic individuals and that these
differences would increase over time.
Materials and Methods
Ethics statement
The Institutional Ethics Committee of the University of Lausanne approved the CoLaus and
subsequently the PsyCoLaus study. All participants signed a written informed consent after
having received a detailed description of the goal and funding of the study.
Study participants and design
The data of the present paper stemmed from CoLaus|PsyCoLaus [22, 23], a cohort study de-
signed to prospectively assess mental disorders and cardiovascular risk factors (CVRFs) in the
general population. Blood and plasma samples were also collected for the study of biomarkers
and genetic variants.
The study participants were selected from a random sample of 19’830 residents (35%) of the
city of Lausanne, in the age range of 35 to 75 years, derived from the electronic database of the
entire population of the 1st January 2003. Letters were sent to all subjects and among respon-
dents (n = 15’109) a final sample of 6736 subjects agreed to participate in CoLaus after having
received additional information regarding the study. The baseline somatic assessment for the
CoLaus study (n = 6736) was conducted between June 2003 and May 2006 and has been de-
scribed in detail elsewhere [22]. In a second step, we asked the 5535 subjects aged between 35
and 66 years to participate in PsyCoLaus. Subsequently, 67% of them accepted to take part in
the psychiatric evaluation, and the final sample was comprised of 3719 individuals who under-
went both the somatic and psychiatric exams (PsyCoLaus study) [23]. Ninety-two percent of
them were Caucasians. The gender distribution of the PsyCoLaus sample (47% men) did not
significantly differ from that of the general population in the same age range (mean age ± SD:
50.9 ± 8.8 years). Although the youngest 5-year band of the cohort was underrepresented and
the oldest 5-year band overrepresented, participants of PsyCoLaus (mean age ± SD: 50.9 ± 8.8
years) and individuals who refused to participate revealed comparable scores on the General
Health Questionnaire [24], French translation [25], a self-rating instrument completed at the
somatic exam.
Among the 3174 participants who had complete data for agoraphobia from the psychiatric
evaluation at baseline, the majority also took part in the somatic follow-up evaluation. At
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follow-up 3100, 2792, 2792, 2792, and 2679 subjects provided a blood sample for measure-
ments of the pro-inflammatory markers CRP, IL-1β, IL-6, TNF-α, and adiponectin, respective-
ly. Participants with high-sensitivity CRP> 10 mg/L (n = 210) at baseline and follow-up were
excluded from the analysis, as these values are likely to be a sign of acute infection, resulting in
a final study sample of 2890 subjects. The average duration between the somatic baseline and
follow-up assessments was 5.5 ± 0.4 years (range 4.7–8.5). The average duration between so-
matic and psychiatric evaluations at baseline was 1.3 ± 0.5 years (0.2–5.7). There was no signifi-
cant difference in time from somatic to psychiatric evaluation (p = 0.326) and time to the
follow-up assessment (p = 0.414) for agoraphobics compared to the rest of the sample
(Table 1).
Assessment of agoraphobia
Diagnostic information on lifetime agoraphobia was collected using the semi-structured Diag-
nostic Interview for Genetic Studies (DIGS) [26]. The DIGS also assessed the severity of agora-
phobia by a Global Assessment of Functioning score (GAF score) specific to the agoraphobia
section. The DIGS was developed by the National Institute of Mental Health (NIMH) Molecu-
lar Genetics Initiative to obtain a more precise assessment of phenotypes through a wide spec-
trum of DSM-IV Axis I criteria. Psychiatric diagnoses were assigned according to the DSM-IV.
We used the French translation of the DIGS [27] with excellent inter-rater reliability in terms
of kappa and Yule’s Y coefficients for major mood and psychotic disorders [28] as well as for
substance use disorders [29], and 6-week test-retest reliability which was somewhat lower but
still in the fair to good ranges [28, 29]. The inter-rater reliability for specific anxiety disorders
was very good, whereas the 6-week test-retest reliability estimates were in the fair or good
ranges [30]. Interviewers were required to be psychologists or psychiatrists, who were trained
over a 2-month period. Their training included rating tapes and supervised co-ratings. To pro-
vide ongoing supervision throughout the study, each interview and diagnostic assignment was
reviewed by an experienced senior psychologist. The psychiatric investigation was conducted
approximately one year after the baseline somatic examination.
Assessment of proinflammatory markers
Blood sampling to determine inflammatory levels took place at both the baseline and follow-up
assessments. Venous blood samples (50 mL) were drawn in the fasting state and allowed to
clot. Serum was preferred to plasma, as it has been shown that different anticoagulants may af-
fect absolute cytokine levels differently [31, 32]. High-sensitivity CRP was assessed by immu-
noassay and latex HS (IMMULITE 1000-High, Diagnostic Products Corporation, LA, CA,
USA) with maximum intra- and interbatch coefficients of variation of 1.3% and 4.6%, respec-
tively. Serum samples were kept at -80°C before assessment of IL-1β, IL-6, and TNF-α and sent
on dry ice to the laboratory. Levels of these cytokines were measured using a multiplexed parti-
cle-based flow cytometric cytokine assay [33].
This methodology yields cytokine concentrations correlating well with those obtained by
other methods such as ELISA [34, 35]. Milliplex kits were purchased fromMillipore (Zug,
Switzerland). The procedures closely followed the manufacturer’s instructions. The analysis
was conducted using a conventional flow cytometer (FC500 MPL, BeckmanCoulter, Nyon,
Switzerland). Good agreement between signal and cytokine was found within the assay range
(R2 0.99). Intra- and inter-assay coefficients of variation (CV) were respectively 15% and
16.7% for IL-1β, 16.9% and 16.1% for IL-6 and 12.5% and 13.5% for TNF-α. Adiponectin was
assessed by ELISA (R&D Systems, Inc, Minneapolis, USA) with a maximum inter-assay CV of
Agoraphobia and Low-Grade Inflammation
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Table 1. Baseline characteristics of the whole sample and per group with and without agoraphobia.
All No agoraphobia Agoraphobia p value
(n = 2890) (n = 2766, 95.7%) (n = 124, 4.3%)
Duration between somatic and psychiatric evaluations at baseline,
years
1.3±0.5 (0.2–5.7) 1.3±0.5 (0.2–5.7) 1.3±0.4 (0.6–4.3) 0.326
Length of follow-upa, years 5.5±0.4 (4.7–8.5) 5.5±0.4 (4.7–8.5) 5.5±0.4 (5.1–8.2) 0.414







Socioeconomic statusb 3.4±1.3 (1.0–5.0) 3.5±1.3 (1.0–5.0) 3.2±1.3 (1.0–5.0) 0.040*
Hypertensionc 0.990
No 2309 (79.8%) 2207 (79.8%) 99 (79.8%)
Yes 584 (20.2%) 559 (20.2%) 25 (20.2%)
Body mass index 0.205
Underweight (BMI<18.5 kg/m2) 49 (1.7%) 44 (1.6%) 5 (4.0%)
Normal (18.5 kg/m2BMI<25 kg/m2) 1504 (52.0%) 1440 (52.1%) 64 (51.6%)
Overweight (25 kg/m2BMI<30 kg/m2) 1002 (34.7%) 959 (34.7%) 43 (34.7%)
Obesity (BMI30 kg/m2) 335 (11.6%) 323 (11.7%) 12 (9.7%)
Glucose, fasting state mmol/L 5.5±1.0 (0.3–21.2) 5.5±1.0 (0.3–21.2) 5.5±1.1 (4.2–13.8) 0.598
Total cholesterol/HDL-cholesterol ratio 3.6±1.1 (1.4–12.0) 3.6±1.1 (1.4–12.0) 3.5±1.1 (1.8–7.7) 0.574
Smoking status 0.040*
Never 1140 (39.5%) 1102 (39.8%) 38 (30.7%)
Former/Current 1750 (60.5%) 1664 (60.2%) 86 (69.3%)
Alcohol consumption 0.032*
Nondrinkers 713 (24.7%) 674 (24.4%) 39 (31.5%)
Low (1–6 drinks/week) 1118 (38.7%) 1068 (38.6%) 50 (40.3%)
Moderate (7–13 drinks /week) 594 (20.6%) 568 (20.5%) 26 (21.0%)
High (14+ drinks /week) 465 (16.1%) 456 (16.5%) 9 (7.3%)
Leisure physical activityd 0.265
No 1281 (44.3%) 1220 (44.1%) 61 (49.2%)
Yes 1609 (55.7%) 1546 (55.9%) 63 (50.8%)
Major depressive disorder <0.001**
No 1630 (56.4%) 1581 (57.2%) 49 (39.5%)
Yes 1260 (43.6%) 1185 (42.8%) 75 (60.5%)
Other anxiety disorderse <0.001**
No 2297 (79.5%) 2239 (80.9%) 58 (46.8%)
Yes 593 (20.5%) 527 (19.1%) 66 (53.2%)
Drug dependencef 0.334
No 2812 (97.3%) 2693 (97.4%) 119 (96.0%)
Yes 77 (2.3%) 72 (2.6%) 5 (4.0%)
Data are given as mean ± standard deviation (range) or percentage value.
Statistical analyses used Mann-Whitney-U or Pearson’s chi-square test (* p < 0.05, ** p < 0.001).
SES, socioeconomic status; HDL, high-density lipoprotein; BMI, Body mass index.
a Duration between somatic evaluation at baseline and somatic evaluation at follow-up.
b A value of “3” represents an SES of III (middle class) on the Hollingshead Scale.
c Systolic blood pressure  140 mmHg and/or diastolic blood pressure  90 mmHg.
d Physically active at least or more than 20 minutes twice a week.
e Generalized anxiety disorder, panic disorder, posttraumatic stress disorder, and/or social phobia.
f Marijuana, cocaine, solvent, hallucinogen, stimulant, sedative or/and narcotic dependence.
doi:10.1371/journal.pone.0123757.t001
Agoraphobia and Low-Grade Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0123757 April 13, 2015 5 / 19
8.3% and a maximum intra-assay CV of 8.3%. For quality control, repeated measurements
were conducted in 80 subjects randomly drawn from the initial sample.
Assessment of covariates
The somatic exam comprised measurements of body weight, height and blood pressure (tripli-
cate measure on the left arm after at least a 10-min rest in the seated position). Venous blood
samples were drawn from each participant after an overnight fast to measure the levels of glu-
cose, total cholesterol, and high-density lipoprotein (HDL)-cholesterol. Continuous values of
fasting blood glucose and the total cholesterol/HDL-cholesterol-ratio were used. According to
the World Health Organization guidelines, overweight was defined as a body mass index
(BMI) of 25 and to 30 kg/m2 and obesity was defined as a BMI 30 kg/m2 [36]. A diagnosis of
hypertension was assigned in the case of systolic blood pressure 140 mmHg and/or diastolic
blood pressure 90 mmHg. Information on gender and age, socioeconomic status (SES),
physical inactivity and nicotine and alcohol consumption was taken from the DIGS. SES was
assessed using the Hollingshead scale [37]. A subject was considered as physically active when
he or she reported regular physical exercise for at least 20 minutes twice a week. Regular nico-
tine consumption was defined as a current or past history of smoking. Alcohol intake was as-
sessed by self-reported alcohol consumption in the last seven days, expressed as the number of
standard drinks. A standard drink was defined as a glass of wine, a bottle of beer or a shot of
spirits, approximating 10–12 g ethanol [38]. Subjects were categorized as nondrinkers, low (1–
6 drinks/week), moderate (7-13/week) and high (14+/week) alcohol consumers. Question-
naire-based data on alcohol consumption have been shown to correlate well with daily alcohol
intake over the previous 4 years [39]. Lifetime major depressive disorder (MDD), other anxiety
disorders (generalized anxiety disorder, panic disorder, posttraumatic stress disorder, social
phobia) and drug dependence (marijuana, cocaine, solvent, hallucinogen, stimulant, sedative
or/and narcotic dependence) were collected using the DIGS.
Statistical analysis




18.0 statistical software package
(IBM Corporation, New York, USA) and the Statistical Analysis System, version 9.2 for Win-
dows (SAS Institute Inc., Cary, NC, USA). Data are presented as means ± standard deviation
(range) or absolute numbers and percentages for continuous and categorical variables, respec-
tively. We categorized the participants into two groups, those with and those without agora-
phobia. To detect significant differences in covariates between the two groups, we applied the
Mann-Whitney-U and Pearson’s chi-square test for continuous and categorical variables, re-
spectively. Lower limits of detection (LOD) for IL-1β, IL-6 and TNF-α were 0.2 pg/ml. Unde-
tectable measures for IL-1β, IL-6 and TNF-α at baseline and follow-up were replaced by half
the LOD (i.e., 0.1 pg/ml) as was previously suggested [33–35]. For adiponectin, and high-sensi-
tivity CRP, all values were detectable at baseline and at follow-up. Given that as many as 37%
and 25% of the values of IL-1β at baseline and at follow-up respectively were below the LOD,
we dichotomized this variable at the median and applied logistic regression models. For subse-
quent analyses, inflammatory measures (CRP, IL-6, TNF-α and adiponectin) were log10-trans-
formed to normalize distributions. The sum of log10-transformed and z-scored high-
sensitivity CRP, IL-6 and TNF-α were used to create a composite score of inflammatory mark-
ers at baseline and at follow-up [40]. Only participants who had data available for all three of
these markers were included in these analyses (n = 2569).
Associations between agoraphobia at baseline and CRP, IL-6, TNF-α, adiponectin and the
composite score of inflammatory markers outcome levels at baseline or at follow-up were
Agoraphobia and Low-Grade Inflammation
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determined using multiple linear regression models, separately for each outcome variable. For
the associations between agoraphobia at baseline and inflammatory markers at follow-up, five
models of increasing complexity were computed; first (model 1) only with an adjustment for
value of the corresponding inflammatory measure at baseline and the duration between somatic
evaluation at baseline and at follow-up (i.e., length of follow-up), and, subsequently (models
2–5), with the same adjustments as for model 1 and additional adjustments for demographic
and health-related covariates. In model 2, we made adjustments for inflammatory measures at
baseline and sociodemographic characteristics (age, gender, SES). In model 3, we additionally
adjusted for physical CVRFs (hypertension, BMI, glucose, total cholesterol/HDL-cholesterol),
in model 4, for behavioral CVRFs (smoking, alcohol consumption, physical activity), and finally,
in model 5, for other relevant lifetime psychiatric disorders: major depressive disorders, other
anxiety disorders (generalized anxiety disorder, panic disorder, posttraumatic stress disorder,
social phobia) and drug dependence (marijuana, cocaine, solvent, hallucinogen, stimulant, seda-
tive or/and narcotic dependence). Statistical significance was considered at p< 0.05. We did not
adjust p-values for multiple comparisons for the following two reasons [41, 42]: a) the hypothe-
sized relationships between agoraphobia and inflammatory measures were specified a priori;
and b) the examined inflammatory measures are actual observations in nature and all indicative
of the same biological process (i.e., chronic low-grade systemic inflammation).
Results
Characteristics of study participants
Baseline characteristics of the study sample (n = 2890) are presented in Table 1. On average,
participants were 50 years old and 53% were female. Concerning CVRFs, quite a sizeable per-
centage of participants were former or current smokers (61%). Thirty-seven percent of partici-
pants reported moderate-to-high alcohol consumption and 44% were physically inactive.
Lifetime agoraphobia was detected in 124 individuals (4.3% of all participants).
The comparison between agoraphobics and non-agoraphobics on demographic and health
characteristics revealed significantly more women and more smokers, but fewer alcohol con-
sumers of alcohol in the group with agoraphobia. Individuals with agoraphobia also showed a
significantly higher prevalence of concomitant anxiety and major depressive disorders than
their non-agoraphobic counterparts. The proinflammatory biomarkers at baseline (Table 2)
did not differ significantly between subjects with agoraphobia and controls, even after adjust-
ment for all covariates.
Inflammatory measures at follow-up
The comparison of circulating levels of inflammatory measures at baseline and follow-up be-
tween agoraphobics and non-agoraphobics is presented in Table 2 (log10-transformed
means ± standard deviations, values for IL-1β are given as prevalence). Mean values of the
log10-transformed biomarkers levels did not significantly differ between agoraphobics and
non-agoraphobics at baseline. After adjusting for CRP at baseline and all further covariates,
mean log10-transformed CRP at follow-up was higher in agoraphobics than in non-agorapho-
bics at baseline. This absolute increase was statistically significant (Table 3 and Table 4; β =
0.087 (95%-CI 0.024 to 0.151; p = 0.007). The effect size of agoraphobia was similar to that of
overweight, but lower than those of underweight and obesity. In contrast, it was higher than
the effect sizes of smoking and alcohol consumption. Similarly, TNF-α levels were significantly
higher among subjects with agoraphobia than among those without and the significance of this
association was preserved in all five models (Table 3 and Table 7; β = 0.089 (95%-CI 0.003 to
0.174; p = 0.042). In addition, the effect size of agoraphobia for TNF- α was higher than those
Agoraphobia and Low-Grade Inflammation
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of all the other covariates, except for drug dependence. In contrast to the other proinflamma-
tory markers, the cardio-protective biomarker adiponectin was significantly lower in persons
with than those without agoraphobia after adjustment for covariates (models 1–5; Table 3 and
Table 8; β = -0.053 (95%-CI -0.101 to -0.005; p = 0.032)). The effect size of agoraphobia for adi-
ponectin was lower than those of gender, obesity and underweight, but higher than those of
overweight, hypertension and alcohol consumption. Levels of IL-6 (Table 3 and Table 6) and
IL-1β (Table 3 and Table 5) did not significantly differ between groups. The composite score of
proinflammatory markers (including CRP, IL-6 and TNF-α) at follow-up was higher (model 5:
β = 0.578 (95%-CI 0.241–0.915; Table 3 and Table 9) among subjects suffering from lifetime
agoraphobia at baseline. The severity of agoraphobia (mean GAF score ± SD: 53.9 ± 0.9 (range:
30–99)) was not significantly associated with the levels of the proinflammatory markers.
Discussion
In this population-based sample of 2890 Swiss adults, individuals with agoraphobia, relative to
their non-agoraphobic counterparts, showed a prospective increase in levels of circulating bio-
markers indicating a low-grade inflammatory state over time. Especially, levels of CRP, but
also of TNF-α increased over time, while the level of cardio-protective adiponectin significantly
decreased from baseline to follow-up. The direction of the association between agoraphobia
and IL-6 was also as hypothesized direction, although the association was not significantly, sug-
gesting insufficient statistical power. Interestingly, the proinflammatory biomarkers and the
adipo(cyto)kine adiponectin showed no difference between the two groups at baseline. The in-
triguing finding of discrepancies between the results from baseline and follow-up were not ex-
plained by the serial adjustments for potential confounders (including the length of follow-up).
However, this might support the notion that the agoraphobic individuals in our sample are
more vulnerable to a progressive immune function dysregulation over time. This might be-
come rather evident at the age range examined (35–67 years).
Our findings of an association between agoraphobia and low-grade inflammation concur
with studies on individuals with PTSD [2–5, 7, 11]. Whether psychobiological mechanisms, in-
cluding HPA axis dysfunction, which have been identified to possibly link PTSD with
Table 2. Associations between lifetime agoraphobia status at baseline and inflammatory measures at baseline and follow-up.
Inﬂammatory markers at baseline Inﬂammatory markers at follow-up
No agoraphobia Agoraphobia p value No agoraphobia Agoraphobia p value
CRPa (mg/l) 0.01±0.43 (n = 2766) 0.01±0.41 (n = 124) 0.851 0.06±0.40 (n = 2766) 0.14±0.43 (n = 124) 0.026
Interleukin-1βb (pg/ml) 47.8% (n = 2671) 46.3% (n = 121) 0.748 54.8% (n = 2671) 50.4% (n = 121) 0.343
Interleukin-6a (pg/ml) 0.15±0.67 (n = 2671) 0.16±0.68 (n = 121) 0.929 0.47±0.77 (n = 2671) 0.56±0.78 (n = 121) 0.217
TNF-αa (pg/ml) 0.46±0.40 (n = 2671) 0.45±0.43 (n = 121) 0.834 0.65±0.47 (n = 2671) 0.74±0.43 (n = 121) 0.042
Adiponectina (mg/l) 0.89±0.30 (n = 2559) 0.91±0.28 (n = 120) 0.610 0.58±0.30 (n = 2559) 0.56±0.34 (n = 120) 0.533
Composite scorea,c -0.07±2.02 (n = 2457) -0.08±1.98 (n = 112) 0.963 -0.07±1.98 (n = 2457) 0.50±1.95 (n = 112) 0.003
Values for inﬂammatory measures are given as unadjusted log10-transformed means ± standard deviation, values for interleukin-1β are given
as prevalence.
CRP, C-reactive protein; TNF, tumor necrosis factor.
a Multiple regression with log10 transformed cytokine or CRP or adiponectin.
b Logistic regression with interleukin-1β concentration dichotomized at the median.
c Composite score of inﬂammatory markers includes CRP, interleukin-6 and TNF-α. Only participants who had data available for all three of these markers
were included in these analyses.
doi:10.1371/journal.pone.0123757.t002
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inflammation, also apply to agoraphobics needs to be investigated further in carefully planned
mechanistic studies.
To our knowledge this is the first study that examined the prospective associations between
agoraphobia and changes in proinflammatory biomarkers in a large population-based sample.
The strength of the study is the use of both a thorough biological evaluation and a comprehen-
sive psychiatric assessment which allowed us to collect data on environmental and health-relat-
ed risk factors as well as on major psychiatric diseases. The overall prevalence of agoraphobia
in this study was 4.3%, which is situated within the lower bound of prevalences reported in
other studies, ranging from 1% to 22% [18]. We found a striking gender difference in the prev-
alence of agoraphobia with almost 4 out of 5 participants of the agoraphobic group being fe-
male (81%). This prevalence estimate is similar to that of another study reporting a women to
men ratio of 4:1 for agoraphobia [43].
The PsyCoLaus study was designed to better understand the relationship between psychiat-
ric disorders and cardiovascular diseases (CVD) [23], including the potential mechanisms in-
volved in this link, such as chronic low-grade inflammation. Meta-analyses suggest that the
prospective risk of incident coronary heart disease (CHD) is increased in individuals with an
anxiety disorder, including phobic anxiety [44], as well as in those with elevated levels of in-
flammatory measures, including CRP and TNF-α [45, 46]. Enhanced inflammation is a key
process in atherosclerosis, which, for instance, via crosstalking with the endothelium and coag-
ulation system promotes endothelial dysfunction and prothrombotic changes that critically
contribute to atherosclerosis progression and ultimately acute coronary syndromes [47, 48].
Abundant biobehavioral research strongly suggests that psychosocial risk factors, including
psychiatric disorders may affect all of the biological processes that lead from initiation to overt
manifestation of atherothrombotic diseases, a process that may take many decades to become
clinically apparent [49, 50]. Taken together, this research together with findings from our
study may imply that a chronic low-grade inflammatory state in agoraphobia contributes to
atherothrombotic CVD in patients with agoraphobia independent of sociodemographic, life
style and physical CVRFs, and other major psychiatric diseases.
This study should be placed into the context of at least two notable limitations. First, as a
consequence of avoidance behaviors (e.g., travel to the study site), some of the most severe
cases of agoraphobia may not have been included in our sample. This may limit the generaliza-
tion of our findings to all patients with agoraphobia, and particularly to those who are referred
to a mental health care setting for treatment. However, as persons with severe agoraphobia
could potentially show even higher levels of inflammatory markers, our results are likely to en-
tail a conservative estimate. Second, the gap between the psychiatric and somatic assessments
was about one year, which might have diluted temporal relationships between agoraphobia
and inflammation, thereby potentially explaining why IL-1β and IL-6 levels showed no signifi-
cant associations. Also, this between assessment gap entailed the risk that some individuals at-
tributed to agoraphobia had produced cytokine levels that preceded the onset of the disorder.
In this regard, it was shown that anxiety symptoms are part of cytokine-induced sickness be-
havior resulting from peripheral inflammation signaling the brain to initiate adaptive behaviors
in various states of immune activation [51]. However, full-blown agoraphobic symptoms are
not usually viewed as typical for sickness behavior and, moreover, the associations in our study
showed high robustness, even after adjustment for a set of important CVRFs.
To sum up, our study demonstrates that agoraphobia predicted an increase in low-grade
systematic inflammation over time in comparison to a control group without agoraphobia.
This finding is clinically relevant, suggesting that agoraphobia might exaggerate inflammation
activity which, further downstream, might result in vascular pathology and ultimately athero-
sclerotic vascular disease. However, longitudinal studies with CVD endpoints are needed to
Agoraphobia and Low-Grade Inflammation
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confirm this possibility. Future studies should also investigate which signs and symptoms of
agoraphobia show a particularly strong association with chronic low-grade inflammation.
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